Literature DB >> 27284482

Stereotactic body radiotherapy for the pancreas: a critical review for the medical oncologist.

Samuel K Kim1, Cheng-Chia Wu1, David P Horowitz1.   

Abstract

With recent advances in imaging modalities and radiation therapy, stereotactic body radiotherapy (SBRT) has allowed for the delivery of high doses of radiation with accuracy and precision. As such, SBRT has generated favorable results in the treatment of several cancers. Although the role of radiation has been controversial for the treatment of pancreatic ductal adenocarcinoma (PDAC) due to rather lackluster results in clinical trials, SBRT may offer improved outcomes, enhance the quality of life, and aid in palliative care settings for PDAC patients. This review delineates the role of SBRT in the treatment of PDAC, presents the defining principles of radiation biology and the radiation oncology work flow, and discusses the prospects of new treatment regimens involving tumor immunology and radiation therapy.

Entities:  

Keywords:  Pancreatic ductal adenocarcinoma (PDAC); radiation oncology; radiotherapy; stereotactic body radiotherapy (SBRT)

Year:  2016        PMID： 27284482      PMCID： PMC4880784          DOI： 10.21037/jgo.2015.10.01

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN： 2078-6891


  54 in total

1.  Stereotactic body radiation therapy for nonresectable tumors of the pancreas.

Authors:  Kush Goyal; Douglas Einstein; Rafael A Ibarra; Min Yao; Charles Kunos; Rod Ellis; James Brindle; Deepjot Singh; Jeffrey Hardacre; Yuxia Zhang; Jeffrey Fabians; Gary Funkhouser; Mitchell Machtay; Juan R Sanabria
Journal:  J Surg Res       Date:  2011-09-05       Impact factor: 2.192

2.  Targeting anionic phospholipids on tumor blood vessels and tumor cells.

Authors:  Philip E Thorpe
Journal:  Thromb Res       Date:  2010-04       Impact factor: 3.944

3.  Stereotactic body radiation therapy for inoperable early stage lung cancer.

Authors:  Robert Timmerman; Rebecca Paulus; James Galvin; Jeffrey Michalski; William Straube; Jeffrey Bradley; Achilles Fakiris; Andrea Bezjak; Gregory Videtic; David Johnstone; Jack Fowler; Elizabeth Gore; Hak Choy
Journal:  JAMA       Date:  2010-03-17       Impact factor: 56.272

4.  [Possibilities of stereotactic radiotherapy in the palliative treatment of patients with pancreatic cancer].

Authors:  S I Tkachev; S V Medvedev; Ya R Znatkova; D S Romanov; E A Nogovitsyn; P V Bulychkin; T V Yurieva; R A Gutnik; I P Yazhgunovich; A V Berdnik; Yu B Bykova; I S Bazin; D I Fedoseenko
Journal:  Vopr Onkol       Date:  2015

5.  The role of radiotherapy in management of pancreatic cancer.

Authors:  Fen Wang; Parvesh Kumar
Journal:  J Gastrointest Oncol       Date:  2011-09

6.  Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma.

Authors:  Morten Hoyer; Henrik Roed; Lisa Sengelov; Anders Traberg; Lars Ohlhuis; Jorgen Pedersen; Hanne Nellemann; Anne Kiil Berthelsen; Frey Eberholst; Svend Aage Engelholm; Hans von der Maase
Journal:  Radiother Oncol       Date:  2005-07       Impact factor: 6.280

7.  Phase I safety and pharmacokinetic study of bavituximab, a chimeric phosphatidylserine-targeting monoclonal antibody, in patients with advanced solid tumors.

Authors:  David E Gerber; Alison T Stopeck; Lucas Wong; Lee S Rosen; Philip E Thorpe; Joseph S Shan; Nuhad K Ibrahim
Journal:  Clin Cancer Res       Date:  2011-10-11       Impact factor: 12.531

Review 8.  Targeting roles of inflammatory microenvironment in lung cancer and metastasis.

Authors:  Lin Shi; Lingyan Wang; Jiayan Hou; Bijun Zhu; Zhihui Min; Miaomiao Zhang; Dongli Song; Yunfeng Cheng; Xiangdong Wang
Journal:  Cancer Metastasis Rev       Date:  2015-06       Impact factor: 9.264

9.  Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.

Authors:  Luana Calabrò; Aldo Morra; Ester Fonsatti; Ornella Cutaia; Giovanni Amato; Diana Giannarelli; Anna Maria Di Giacomo; Riccardo Danielli; Maresa Altomonte; Luciano Mutti; Michele Maio
Journal:  Lancet Oncol       Date:  2013-09-11       Impact factor: 41.316

10.  Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma.

Authors:  Joseph M Herman; Daniel T Chang; Karyn A Goodman; Avani S Dholakia; Siva P Raman; Amy Hacker-Prietz; Christine A Iacobuzio-Donahue; Mary E Griffith; Timothy M Pawlik; Jonathan S Pai; Eileen O'Reilly; George A Fisher; Aaron T Wild; Lauren M Rosati; Lei Zheng; Christopher L Wolfgang; Daniel A Laheru; Laurie A Columbo; Elizabeth A Sugar; Albert C Koong
Journal:  Cancer       Date:  2014-12-23       Impact factor: 6.860
View more
  12 in total

1.  Selective EGLN Inhibition Enables Ablative Radiotherapy and Improves Survival in Unresectable Pancreatic Cancer.

Authors:  Tara N Fujimoto; Lauren E Colbert; Yanqing Huang; Jessica M Molkentine; Amit Deorukhkar; Laura Baseler; Meifang Yu; Daniel Lin; Sonal Gupta; Peter K Cabeceiras; Charles V Kingsley; Ramesh C Tailor; Gabriel O Sawakuchi; Eugene J Koay; Helen Piwnica-Worms; Anirban Maitra; Cullen M Taniguchi
Journal:  Cancer Res       Date:  2019-05-01       Impact factor: 12.701

2.  The BET inhibitor I-BET762 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine.

Authors:  Fang Xie; Mei Huang; Xiansheng Lin; Chenhai Liu; Zhen Liu; Futao Meng; Chao Wang; Qiang Huang
Journal:  Sci Rep       Date:  2018-05-25       Impact factor: 4.379

3.  One- vs. Three-Fraction Pancreatic Stereotactic Body Radiation Therapy for Pancreatic Carcinoma: Single Institution Retrospective Review.

Authors:  Philip Anthony Sutera; Mark E Bernard; Beant S Gill; Kamran K Harper; Kimmen Quan; Nathan Bahary; Steven A Burton; Herbert Zeh; Dwight E Heron
Journal:  Front Oncol       Date:  2017-11-14       Impact factor: 6.244

4.  Radiomics-Based Outcome Prediction for Pancreatic Cancer Following Stereotactic Body Radiotherapy.

Authors:  Elsa Parr; Qian Du; Chi Zhang; Chi Lin; Ahsan Kamal; Josiah McAlister; Xiaoying Liang; Kyle Bavitz; Gerard Rux; Michael Hollingsworth; Michael Baine; Dandan Zheng
Journal:  Cancers (Basel)       Date:  2020-04-24       Impact factor: 6.639

Review 5.  Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options.

Authors:  Derya Kabacaoglu; Katrin J Ciecielski; Dietrich A Ruess; Hana Algül
Journal:  Front Immunol       Date:  2018-08-15       Impact factor: 7.561

6.  Dosimetric and radiobiological comparison of treatment plan between CyberKnife and EDGE in stereotactic body radiotherapy for pancreatic cancer.

Authors:  Zhi-Tao Dai; Li Ma; Ting-Ting Cao; Lian Zhu; Man Zhao; Ning Li
Journal:  Sci Rep       Date:  2021-02-18       Impact factor: 4.379

7.  Immune checkpoint blockade can synergize with radiation therapy, even in tumors resistant to checkpoint monotherapy.

Authors:  Jan Dörrie
Journal:  EMBO Mol Med       Date:  2017-02       Impact factor: 12.137

8.  Prognostic Factors for Elderly Patients Treated With Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma.

Authors:  Philip A Sutera; Mark E Bernard; Hong Wang; Dwight E Heron
Journal:  Front Oncol       Date:  2018-07-27       Impact factor: 6.244

9.  Impact of abdominal compression on setup error and image matching during radical abdominal radiotherapy.

Authors:  Kwun-Ye Chu; Rosie Cooke; Frank Van den Heuvel; Somnath Mukherjee; Maria A Hawkins
Journal:  Tech Innov Patient Support Radiat Oncol       Date:  2019-12-16

Review 10.  Stereotactic ablative radiotherapy for oligometastatic breast cancer in elderly patients.

Authors:  Ignacio Morales-Orue; Juan Zafra-Martin; Laura Garcia; Rodolfo Chicas-Sett; Juan Castilla-Martinez; Maria Auxiliadora Cabezon; Javier Burgos; Marta Lloret; Pedro C Lara
Journal:  Transl Cancer Res       Date:  2020-01       Impact factor: 1.241
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.